At present, long-acting GLP-1 agonist holds the maximum share of the GLP-1 market and this trend is likely to remain the same in the forthcoming years
Expanding oral GLP-1 options could help many patients access effective treatment who might otherwise never start therapy because they dont want injections
While you may not see a dramatic change on the scale within these first seven days, your metabolic machinery is being recalibrated
By modulating these receptors, scientists might be able to downregulate inflammatory pathways even in the presence of proinflammatory mediators such as cytokine interferon-gamma, TNF-alpha, IL-1, IL-6, IL-8, and growth-regulated oncogene-alpha
Moreover, theranostic liposomes, which co-deliver drugs and imaging agents, have been developed to enable simultaneous therapy and real-time monitoring [121]